CMAJ • October 25, 2005; 173 (9). First published September 22, 2005; doi:10.1503/cmaj.050978
© 2005 CMA Media Inc. or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Abridged Version
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pépin, J.
Right arrow Articles by Cossette, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pépin, J.
Right arrow Articles by Cossette, B.
Related Collections
Right arrow Patient safety, clinical risk, medical error
Right arrow Clostridium difficile
Right arrowRelated Article

Mortality attributable to nosocomial Clostridium difficile–associated disease during an epidemic caused by a hypervirulent strain in Quebec

Jacques Pépin, Louis Valiquette and Benoit Cossette

From the Department of Microbiology and Infectious Diseases, University of Sherbrooke (Pépin, Valiquette), and the Department of Pharmacy, Centre hospitalier universitaire de Sherbrooke (Cossette), Sherbrooke, Que.


View this table:

[in a new window]
  		Table 1.

 

View this table:

[in a new window]
  		Table 2.

 

View this table:

[in a new window]
  		Table 3.

 


View larger version (13K):

[in a new window]
  		Fig. 1: Kaplan–Meier plot showing probability of death since diagnosis among inpatients in whom nosocomial Clostridium difficile–associated disease (CDAD) developed and among matched control subjects without CDAD. No. of days = time since diagnosis of CDAD (cases) or time since reaching the same interval after admission (controls).

 

View this table:

[in a new window]
  		Table 4.